Targovax - Growing list of collaborations and more data in H2
An update from Targovax’s Phase I/II study in unresectable mesothelioma with OCOS-102 was the highlight of Q220 (described in our last note)....
49 Views
Targovax - Confirmatory 12-month mesothelioma update
On 22 June 2020 Targovax reported data from its Phase I/II study in unresectable mesothelioma (a follow up to the first data published in January...
74 Views
Targovax - ONCOS-102 plus durvalumab trial in spotlight
Targovax has announced that one of the trials with ONCOS-102, which is sponsored by Ludwig Institute for Cancer Research, will be in the spotlight...
94 Views
Targovax - More data in 2020 from both clinical trials
Targovax started 2020 with the first randomised data readout from its Phase I/II trial with oncolytic virus ONCOS-102 in unresectable mesothelioma....
465 Views
Targovax - ONCOS-102 set for late-stage development
Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will...
708 Views
No more insights